SCHEMBL5307685

SCHEMBL5307685

NC(=O)N(c1ccc(-c2ccc(OCCN3CCOCC3)c3onc(N)c23)cc1)c1cc(C(F)(F)F)ccc1F

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 9/20 0.58
KIT P10721 7/20 0.58
FLT3 P36888 7/20 0.58
IKBKE Q14164 1/20 0.52
CSF1R P07333 3/20 0.41
FLT1 P17948 3/20 0.41
PDGFRB P09619 2/20 0.41
TEK Q02763 2/20 0.41
HTR2A P28223 2/20 0.40
HTR2C P28335 1/20 0.40
EPHX2 P34913 2/20 0.40
ALOX5AP P20292 2/20 0.39
FEN1 P39748 2/20 0.39
KCNH2 Q12809 2/20 0.39
AURKA O14965 1/20 0.37
PDPK1 O15530 1/20 0.37
DYRK3 O43781 1/20 0.37
ROCK2 O75116 1/20 0.37
RPS6KA5 O75582 1/20 0.37
PRKD3 O94806 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5310826 0.90 KDR (0.69) KDRKITFLT3IKBKECSF1R
SCHEMBL13372708 0.88 KDR (0.53) KDRKITFLT3IKBKECSF1R
SCHEMBL27636370 0.87 IKBKE (0.67) KDRKITFLT3IKBKECSF1R
SCHEMBL27657403 0.83 KDR (0.53) KDRKITFLT3IKBKECSF1R
SCHEMBL422243 0.83 KDR (0.57) KDRKITFLT3IKBKECSF1R
SCHEMBL420441 0.82 KDR (0.82) KDRKITFLT3IKBKECSF1R
SCHEMBL27657281 0.82 KDR (0.47) KDRKITFLT3IKBKECSF1R
SCHEMBL1384424 0.80 KDR (0.73) KDRKITFLT3IKBKECSF1R
SCHEMBL5251524 0.79 KDR (0.50) KDRKITFLT3IKBKECSF1R
SCHEMBL421068 0.78 KDR (0.69) KDRKITFLT3IKBKECSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed